Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532621 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
A NA study, sponsored by Phraxis.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
NCT02532621: Completed NA study, sponsored by Phraxis.
NCT02532621 is a NA study that has completed, run by Phraxis. The registered enrollment target is 158 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532621, a NA study, has completed, sponsored by Phraxis.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
Study Summary
The InterGraft™ Venous Anastomotic Connector provides an endovascular, minimally invasive means for attachment of an arteriovenous graft to a vein in the upper extremity. The InterGraft™ Venous Anastomotic Connector facilitates creation of the arteriovenous graft connection to a vein in support of hemodialysis in subjects with End Stage Renal Disease. The InterGraft™ Venous Anastomotic Connector is used together with conventional suturing of the arterial anastomosis to facilitate creation of an arteriovenous graft in support of hemodialysis in subjects with End Stage Renal Disease.
Primary Outcome
Percentage of subjects free from loss of access of the study graft for hemodialysis
Interventions
- DEVICE Venous InterGraft Connector
- PROCEDURE sutured arterial anastomosis of an implanted vascular graft for hemodialysis
- PROCEDURE hemodialysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2022-01-19 |
| Phase | NA |
What the finished NCT02532621 record still lists
NCT02532621 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Venous InterGraft Connector is the first listed.
NCT02532621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02532621 about?
NCT02532621 is a clinical study titled "Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]". The InterGraft™ Venous Anastomotic Connector provides an endovascular, minimally invasive means for attachment of an arteriovenous graft to a vein in the upper extremity. The InterGraft™ Venous Anastomotic Connector facilitates creation of the arteriovenous graft connection to a vein in support of h...
What is the current status of trial NCT02532621?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2018-02-21. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT02532621?
The interventions under investigation include: Venous InterGraft Connector (DEVICE), sutured arterial anastomosis of an implanted vascular graft for hemodialysis (PROCEDURE), hemodialysis (PROCEDURE).
Who is sponsoring clinical trial NCT02532621?
This trial is sponsored by Phraxis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02532621's enrollment target sits among peer trials
158 654th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI